Taken together, these trials in LGSOC combined with our preclinical data in uterine cancer suggest that RAF/MEK/FAK inhibition may represent a novel strategy with potential clinical efficacy in other biologically aggressive tumors such as poorly differentiated EAC. The gene discussed is MAP2K7; the disease is uterine cancer.